Advertisement

Index by author

April 01, 1996; Volume 49,Issue 4

A

  1. Anyanwutaku, I O

    1. Activities of novel nonglycosidic epipodophyllotoxins in etoposide-sensitive and -resistant variants of human KB cells, P-388 cells, and in vivo multidrug-resistant murine leukemia cells.
      I O Anyanwutaku, X Guo, H X Chen, Z Ji, K H Lee and Y C Cheng
      Molecular Pharmacology April 1996, 49 (4) 721-726;

  2. Arrighi, V

    1. Metabotropic and ionotropic transducers of glutamate signal inversely control cytoplasmic Ca2+ concentration and excitotoxicity in cultured cerebellar granule cells: pivotal role of protein kinase C.
      M Pizzi, P Galli, O Consolandi, V Arrighi, M Memo and P F Spano
      Molecular Pharmacology April 1996, 49 (4) 586-594;

  3. Ashford, M L

    1. Ciclazindol inhibits ATP-sensitive K+ channels and stimulates insulin secretion in CR1-G1 insulin-secreting cells.
      K Lee, R N Khan, I C Rowe, S E Ozanne, A C Hall, E Papadakis, C N Hales and M L Ashford
      Molecular Pharmacology April 1996, 49 (4) 715-720;

B

  1. Ballyk, B

    1. Pharmacological discrimination of GluR5 and GluR6 kainate receptor subtypes by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahyd roisdoquinoline-3 carboxylic-acid.
      R Bleakman, D D Schoepp, B Ballyk, H Bufton, E F Sharpe, K Thomas, P L Ornstein and R K Kamboj
      Molecular Pharmacology April 1996, 49 (4) 581-585;

  2. Barnes, P J

    1. Beta-Adrenoceptor-medicated down-regulation of M2 muscarinic receptors: role of cyclic adenosine 5'-monophosphate-dependent protein kinase and protein kinase C.
      J Rousell, E B Haddad, J C Mak, B L Webb, M A Giembycz and P J Barnes
      Molecular Pharmacology April 1996, 49 (4) 629-635;

  3. Beindl, W

    1. Suramin analogues as subtype-selective G protein inhibitors.
      M Freissmuth, S Boehm, W Beindl, P Nickel, A P Ijzerman, M Hohenegger and C Nanoff
      Molecular Pharmacology April 1996, 49 (4) 602-611;

  4. Blackmore, P F

    1. Unusual steroid specificity of the cell surface progesterone receptor on human sperm.
      P F Blackmore, J F Fisher, C H Spilman and J E Bleasdale
      Molecular Pharmacology April 1996, 49 (4) 727-739;

  5. Bleakman, R

    1. Pharmacological discrimination of GluR5 and GluR6 kainate receptor subtypes by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahyd roisdoquinoline-3 carboxylic-acid.
      R Bleakman, D D Schoepp, B Ballyk, H Bufton, E F Sharpe, K Thomas, P L Ornstein and R K Kamboj
      Molecular Pharmacology April 1996, 49 (4) 581-585;

  6. Bleasdale, J E

    1. Unusual steroid specificity of the cell surface progesterone receptor on human sperm.
      P F Blackmore, J F Fisher, C H Spilman and J E Bleasdale
      Molecular Pharmacology April 1996, 49 (4) 727-739;

  7. Boehm, S

    1. Suramin analogues as subtype-selective G protein inhibitors.
      M Freissmuth, S Boehm, W Beindl, P Nickel, A P Ijzerman, M Hohenegger and C Nanoff
      Molecular Pharmacology April 1996, 49 (4) 602-611;

  8. Bouvier, M

    1. Distinct receptor domains determine subtype-specific coupling and desensitization phenotypes for human beta1- and beta2-adrenergic receptors.
      G Rousseau, F Nantel and M Bouvier
      Molecular Pharmacology April 1996, 49 (4) 752-760;

  9. Buell, G

    1. D2, D3, and D4 dopamine receptors couple to G protein-regulated potassium channels in Xenopus oocytes.
      P Werner, N Hussy, G Buell, K A Jones and R A North
      Molecular Pharmacology April 1996, 49 (4) 656-661;

  10. Bufton, H

    1. Pharmacological discrimination of GluR5 and GluR6 kainate receptor subtypes by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahyd roisdoquinoline-3 carboxylic-acid.
      R Bleakman, D D Schoepp, B Ballyk, H Bufton, E F Sharpe, K Thomas, P L Ornstein and R K Kamboj
      Molecular Pharmacology April 1996, 49 (4) 581-585;

C

  1. Chen, H X

    1. Activities of novel nonglycosidic epipodophyllotoxins in etoposide-sensitive and -resistant variants of human KB cells, P-388 cells, and in vivo multidrug-resistant murine leukemia cells.
      I O Anyanwutaku, X Guo, H X Chen, Z Ji, K H Lee and Y C Cheng
      Molecular Pharmacology April 1996, 49 (4) 721-726;

  2. Chen, J

    1. Differentiating dopamine D2 ligands by their sensitivities to modification of the cysteine exposed in the binding-site crevice.
      J A Javitch, D Fu and J Chen
      Molecular Pharmacology April 1996, 49 (4) 692-698;

  3. Cheng, Y C

    1. Activities of novel nonglycosidic epipodophyllotoxins in etoposide-sensitive and -resistant variants of human KB cells, P-388 cells, and in vivo multidrug-resistant murine leukemia cells.
      I O Anyanwutaku, X Guo, H X Chen, Z Ji, K H Lee and Y C Cheng
      Molecular Pharmacology April 1996, 49 (4) 721-726;

  4. Consolandi, O

    1. Metabotropic and ionotropic transducers of glutamate signal inversely control cytoplasmic Ca2+ concentration and excitotoxicity in cultured cerebellar granule cells: pivotal role of protein kinase C.
      M Pizzi, P Galli, O Consolandi, V Arrighi, M Memo and P F Spano
      Molecular Pharmacology April 1996, 49 (4) 586-594;

D

  1. Dahlman-Wright, K

    1. Modulation of glucocorticoid-inducible gene expression by metal ions.
      Y Makino, H Tanaka, K Dahlman-Wright and I Makino
      Molecular Pharmacology April 1996, 49 (4) 612-620;

E

  1. Eidne, K A

    1. Thyrotropin-releasing hormone-induced subcellular redistribution and down-regulation of G11alpha: analysis of agonist regulation of coexpressed G11alpha species variants.
      P Svoboda, G D Kim, M A Grassie, K A Eidne and G Milligan
      Molecular Pharmacology April 1996, 49 (4) 646-655;

  2. Ernsberger, P

    1. Coupling of I1-imidazoline receptors to diacylglyceride accumulation in PC12 rat pheochromocytoma cells.
      D Separovic, M Kester and P Ernsberger
      Molecular Pharmacology April 1996, 49 (4) 668-675;

F

  1. Fisher, J F

    1. Unusual steroid specificity of the cell surface progesterone receptor on human sperm.
      P F Blackmore, J F Fisher, C H Spilman and J E Bleasdale
      Molecular Pharmacology April 1996, 49 (4) 727-739;

  2. Freissmuth, M

    1. Suramin analogues as subtype-selective G protein inhibitors.
      M Freissmuth, S Boehm, W Beindl, P Nickel, A P Ijzerman, M Hohenegger and C Nanoff
      Molecular Pharmacology April 1996, 49 (4) 602-611;

  3. Fu, D

    1. Differentiating dopamine D2 ligands by their sensitivities to modification of the cysteine exposed in the binding-site crevice.
      J A Javitch, D Fu and J Chen
      Molecular Pharmacology April 1996, 49 (4) 692-698;

  4. Fumagalli, F

    1. Cyclic AMP-dependent regulation of fibroblast growth factor-2 messenger RNA levels in rat cortical astrocytes: comparison with fibroblast growth factor-1 and ciliary neurotrophic factor.
      M A Riva, R Molteni, E Lovati, F Fumagalli, M Rusnati and G Racagni
      Molecular Pharmacology April 1996, 49 (4) 699-706;

G

  1. Galli, P

    1. Metabotropic and ionotropic transducers of glutamate signal inversely control cytoplasmic Ca2+ concentration and excitotoxicity in cultured cerebellar granule cells: pivotal role of protein kinase C.
      M Pizzi, P Galli, O Consolandi, V Arrighi, M Memo and P F Spano
      Molecular Pharmacology April 1996, 49 (4) 586-594;

  2. Giembycz, M A

    1. Beta-Adrenoceptor-medicated down-regulation of M2 muscarinic receptors: role of cyclic adenosine 5'-monophosphate-dependent protein kinase and protein kinase C.
      J Rousell, E B Haddad, J C Mak, B L Webb, M A Giembycz and P J Barnes
      Molecular Pharmacology April 1996, 49 (4) 629-635;

  3. Glashofer, M

    1. Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition.
      J Kim, Q Jiang, M Glashofer, S Yehle, J Wess and K A Jacobson
      Molecular Pharmacology April 1996, 49 (4) 683-691;

  4. Gosselin, G

    1. Effects of nucleotide analogues on human immunodeficiency virus type 1 integrase.
      A Mazumder, N Neamati, J P Sommadossi, G Gosselin, R F Schinazi, J L Imbach and Y Pommier
      Molecular Pharmacology April 1996, 49 (4) 621-628;

  5. Grassie, M A

    1. Thyrotropin-releasing hormone-induced subcellular redistribution and down-regulation of G11alpha: analysis of agonist regulation of coexpressed G11alpha species variants.
      P Svoboda, G D Kim, M A Grassie, K A Eidne and G Milligan
      Molecular Pharmacology April 1996, 49 (4) 646-655;

  6. Guo, X

    1. Activities of novel nonglycosidic epipodophyllotoxins in etoposide-sensitive and -resistant variants of human KB cells, P-388 cells, and in vivo multidrug-resistant murine leukemia cells.
      I O Anyanwutaku, X Guo, H X Chen, Z Ji, K H Lee and Y C Cheng
      Molecular Pharmacology April 1996, 49 (4) 721-726;

H

  1. Haddad, E B

    1. Beta-Adrenoceptor-medicated down-regulation of M2 muscarinic receptors: role of cyclic adenosine 5'-monophosphate-dependent protein kinase and protein kinase C.
      J Rousell, E B Haddad, J C Mak, B L Webb, M A Giembycz and P J Barnes
      Molecular Pharmacology April 1996, 49 (4) 629-635;

  2. Hales, C N

    1. Ciclazindol inhibits ATP-sensitive K+ channels and stimulates insulin secretion in CR1-G1 insulin-secreting cells.
      K Lee, R N Khan, I C Rowe, S E Ozanne, A C Hall, E Papadakis, C N Hales and M L Ashford
      Molecular Pharmacology April 1996, 49 (4) 715-720;

  3. Hall, A C

    1. Ciclazindol inhibits ATP-sensitive K+ channels and stimulates insulin secretion in CR1-G1 insulin-secreting cells.
      K Lee, R N Khan, I C Rowe, S E Ozanne, A C Hall, E Papadakis, C N Hales and M L Ashford
      Molecular Pharmacology April 1996, 49 (4) 715-720;

  4. Hohenegger, M

    1. Suramin analogues as subtype-selective G protein inhibitors.
      M Freissmuth, S Boehm, W Beindl, P Nickel, A P Ijzerman, M Hohenegger and C Nanoff
      Molecular Pharmacology April 1996, 49 (4) 602-611;

  5. Houghton, P J

    1. Separation of resistance to antitumor diarylsulfonylurea agents from collateral sensitivity to mitochondrial toxins.
      L L Shu and P J Houghton
      Molecular Pharmacology April 1996, 49 (4) 595-601;

  6. Hussy, N

    1. D2, D3, and D4 dopamine receptors couple to G protein-regulated potassium channels in Xenopus oocytes.
      P Werner, N Hussy, G Buell, K A Jones and R A North
      Molecular Pharmacology April 1996, 49 (4) 656-661;

I

  1. Ijzerman, A P

    1. Suramin analogues as subtype-selective G protein inhibitors.
      M Freissmuth, S Boehm, W Beindl, P Nickel, A P Ijzerman, M Hohenegger and C Nanoff
      Molecular Pharmacology April 1996, 49 (4) 602-611;

  2. Ikeda, S R

    1. Rat brain cannabinoid receptor modulates N-type Ca2+ channels in a neuronal expression system.
      X Pan, S R Ikeda and D L Lewis
      Molecular Pharmacology April 1996, 49 (4) 707-714;

  3. Imbach, J L

    1. Effects of nucleotide analogues on human immunodeficiency virus type 1 integrase.
      A Mazumder, N Neamati, J P Sommadossi, G Gosselin, R F Schinazi, J L Imbach and Y Pommier
      Molecular Pharmacology April 1996, 49 (4) 621-628;

J

  1. Jacobson, K A

    1. Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition.
      J Kim, Q Jiang, M Glashofer, S Yehle, J Wess and K A Jacobson
      Molecular Pharmacology April 1996, 49 (4) 683-691;

  2. Javitch, J A

    1. Differentiating dopamine D2 ligands by their sensitivities to modification of the cysteine exposed in the binding-site crevice.
      J A Javitch, D Fu and J Chen
      Molecular Pharmacology April 1996, 49 (4) 692-698;

  3. Ji, Z

    1. Activities of novel nonglycosidic epipodophyllotoxins in etoposide-sensitive and -resistant variants of human KB cells, P-388 cells, and in vivo multidrug-resistant murine leukemia cells.
      I O Anyanwutaku, X Guo, H X Chen, Z Ji, K H Lee and Y C Cheng
      Molecular Pharmacology April 1996, 49 (4) 721-726;

  4. Jiang, Q

    1. Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition.
      J Kim, Q Jiang, M Glashofer, S Yehle, J Wess and K A Jacobson
      Molecular Pharmacology April 1996, 49 (4) 683-691;

  5. Jones, K A

    1. D2, D3, and D4 dopamine receptors couple to G protein-regulated potassium channels in Xenopus oocytes.
      P Werner, N Hussy, G Buell, K A Jones and R A North
      Molecular Pharmacology April 1996, 49 (4) 656-661;

  6. Jones, S V

    1. Modulation of the inwardly rectifying potassium channel IRK1 by the m1 muscarinic receptor.
      S V Jones
      Molecular Pharmacology April 1996, 49 (4) 662-667;

K

  1. Kamboj, R K

    1. Pharmacological discrimination of GluR5 and GluR6 kainate receptor subtypes by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahyd roisdoquinoline-3 carboxylic-acid.
      R Bleakman, D D Schoepp, B Ballyk, H Bufton, E F Sharpe, K Thomas, P L Ornstein and R K Kamboj
      Molecular Pharmacology April 1996, 49 (4) 581-585;

  2. Kester, M

    1. Coupling of I1-imidazoline receptors to diacylglyceride accumulation in PC12 rat pheochromocytoma cells.
      D Separovic, M Kester and P Ernsberger
      Molecular Pharmacology April 1996, 49 (4) 668-675;

  3. Khan, R N

    1. Ciclazindol inhibits ATP-sensitive K+ channels and stimulates insulin secretion in CR1-G1 insulin-secreting cells.
      K Lee, R N Khan, I C Rowe, S E Ozanne, A C Hall, E Papadakis, C N Hales and M L Ashford
      Molecular Pharmacology April 1996, 49 (4) 715-720;

  4. Kim, G D

    1. Thyrotropin-releasing hormone-induced subcellular redistribution and down-regulation of G11alpha: analysis of agonist regulation of coexpressed G11alpha species variants.
      P Svoboda, G D Kim, M A Grassie, K A Eidne and G Milligan
      Molecular Pharmacology April 1996, 49 (4) 646-655;

  5. Kim, J

    1. Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition.
      J Kim, Q Jiang, M Glashofer, S Yehle, J Wess and K A Jacobson
      Molecular Pharmacology April 1996, 49 (4) 683-691;

  6. Kimmett, S M

    1. Isolation of N-vinylprotoporphyrin IX after hepatic cytochrome P450 inactivation by 3-[(arylthio)ethyl]sydnone in chick embryos pretreated with phenobarbital, glutethimide, dexamethasone, and beta-naphthoflavone: differential inhibition of ferrochelatase by N-vinylprotoporphyrin regioisomers.
      S M Kimmett, R A Whitney and G S Marks
      Molecular Pharmacology April 1996, 49 (4) 676-682;

L

  1. Lee, K

    1. Ciclazindol inhibits ATP-sensitive K+ channels and stimulates insulin secretion in CR1-G1 insulin-secreting cells.
      K Lee, R N Khan, I C Rowe, S E Ozanne, A C Hall, E Papadakis, C N Hales and M L Ashford
      Molecular Pharmacology April 1996, 49 (4) 715-720;

  2. Lee, K H

    1. Activities of novel nonglycosidic epipodophyllotoxins in etoposide-sensitive and -resistant variants of human KB cells, P-388 cells, and in vivo multidrug-resistant murine leukemia cells.
      I O Anyanwutaku, X Guo, H X Chen, Z Ji, K H Lee and Y C Cheng
      Molecular Pharmacology April 1996, 49 (4) 721-726;

  3. Lewis, D L

    1. Rat brain cannabinoid receptor modulates N-type Ca2+ channels in a neuronal expression system.
      X Pan, S R Ikeda and D L Lewis
      Molecular Pharmacology April 1996, 49 (4) 707-714;

  4. Lovati, E

    1. Cyclic AMP-dependent regulation of fibroblast growth factor-2 messenger RNA levels in rat cortical astrocytes: comparison with fibroblast growth factor-1 and ciliary neurotrophic factor.
      M A Riva, R Molteni, E Lovati, F Fumagalli, M Rusnati and G Racagni
      Molecular Pharmacology April 1996, 49 (4) 699-706;

M

  1. Mak, J C

    1. Beta-Adrenoceptor-medicated down-regulation of M2 muscarinic receptors: role of cyclic adenosine 5'-monophosphate-dependent protein kinase and protein kinase C.
      J Rousell, E B Haddad, J C Mak, B L Webb, M A Giembycz and P J Barnes
      Molecular Pharmacology April 1996, 49 (4) 629-635;

  2. Makino, I

    1. Modulation of glucocorticoid-inducible gene expression by metal ions.
      Y Makino, H Tanaka, K Dahlman-Wright and I Makino
      Molecular Pharmacology April 1996, 49 (4) 612-620;

  3. Makino, Y

    1. Modulation of glucocorticoid-inducible gene expression by metal ions.
      Y Makino, H Tanaka, K Dahlman-Wright and I Makino
      Molecular Pharmacology April 1996, 49 (4) 612-620;

  4. Marks, G S

    1. Isolation of N-vinylprotoporphyrin IX after hepatic cytochrome P450 inactivation by 3-[(arylthio)ethyl]sydnone in chick embryos pretreated with phenobarbital, glutethimide, dexamethasone, and beta-naphthoflavone: differential inhibition of ferrochelatase by N-vinylprotoporphyrin regioisomers.
      S M Kimmett, R A Whitney and G S Marks
      Molecular Pharmacology April 1996, 49 (4) 676-682;

  5. Mazumder, A

    1. Effects of nucleotide analogues on human immunodeficiency virus type 1 integrase.
      A Mazumder, N Neamati, J P Sommadossi, G Gosselin, R F Schinazi, J L Imbach and Y Pommier
      Molecular Pharmacology April 1996, 49 (4) 621-628;

  6. Memo, M

    1. Metabotropic and ionotropic transducers of glutamate signal inversely control cytoplasmic Ca2+ concentration and excitotoxicity in cultured cerebellar granule cells: pivotal role of protein kinase C.
      M Pizzi, P Galli, O Consolandi, V Arrighi, M Memo and P F Spano
      Molecular Pharmacology April 1996, 49 (4) 586-594;

  7. Milligan, G

    1. Thyrotropin-releasing hormone-induced subcellular redistribution and down-regulation of G11alpha: analysis of agonist regulation of coexpressed G11alpha species variants.
      P Svoboda, G D Kim, M A Grassie, K A Eidne and G Milligan
      Molecular Pharmacology April 1996, 49 (4) 646-655;

  8. Molteni, R

    1. Cyclic AMP-dependent regulation of fibroblast growth factor-2 messenger RNA levels in rat cortical astrocytes: comparison with fibroblast growth factor-1 and ciliary neurotrophic factor.
      M A Riva, R Molteni, E Lovati, F Fumagalli, M Rusnati and G Racagni
      Molecular Pharmacology April 1996, 49 (4) 699-706;

N

  1. Nanoff, C

    1. Suramin analogues as subtype-selective G protein inhibitors.
      M Freissmuth, S Boehm, W Beindl, P Nickel, A P Ijzerman, M Hohenegger and C Nanoff
      Molecular Pharmacology April 1996, 49 (4) 602-611;

  2. Nantel, F

    1. Distinct receptor domains determine subtype-specific coupling and desensitization phenotypes for human beta1- and beta2-adrenergic receptors.
      G Rousseau, F Nantel and M Bouvier
      Molecular Pharmacology April 1996, 49 (4) 752-760;

  3. Neamati, N

    1. Effects of nucleotide analogues on human immunodeficiency virus type 1 integrase.
      A Mazumder, N Neamati, J P Sommadossi, G Gosselin, R F Schinazi, J L Imbach and Y Pommier
      Molecular Pharmacology April 1996, 49 (4) 621-628;

  4. Nestler, E J

    1. Induction of chronic Fos-related antigens in rat brain by chronic morphine administration.
      H E Nye and E J Nestler
      Molecular Pharmacology April 1996, 49 (4) 636-645;

  5. Nickel, P

    1. Suramin analogues as subtype-selective G protein inhibitors.
      M Freissmuth, S Boehm, W Beindl, P Nickel, A P Ijzerman, M Hohenegger and C Nanoff
      Molecular Pharmacology April 1996, 49 (4) 602-611;

  6. North, R A

    1. D2, D3, and D4 dopamine receptors couple to G protein-regulated potassium channels in Xenopus oocytes.
      P Werner, N Hussy, G Buell, K A Jones and R A North
      Molecular Pharmacology April 1996, 49 (4) 656-661;

  7. Nye, H E

    1. Induction of chronic Fos-related antigens in rat brain by chronic morphine administration.
      H E Nye and E J Nestler
      Molecular Pharmacology April 1996, 49 (4) 636-645;

O

  1. Ornstein, P L

    1. Pharmacological discrimination of GluR5 and GluR6 kainate receptor subtypes by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahyd roisdoquinoline-3 carboxylic-acid.
      R Bleakman, D D Schoepp, B Ballyk, H Bufton, E F Sharpe, K Thomas, P L Ornstein and R K Kamboj
      Molecular Pharmacology April 1996, 49 (4) 581-585;

  2. Ozanne, S E

    1. Ciclazindol inhibits ATP-sensitive K+ channels and stimulates insulin secretion in CR1-G1 insulin-secreting cells.
      K Lee, R N Khan, I C Rowe, S E Ozanne, A C Hall, E Papadakis, C N Hales and M L Ashford
      Molecular Pharmacology April 1996, 49 (4) 715-720;

P

  1. Pan, X

    1. Rat brain cannabinoid receptor modulates N-type Ca2+ channels in a neuronal expression system.
      X Pan, S R Ikeda and D L Lewis
      Molecular Pharmacology April 1996, 49 (4) 707-714;

  2. Papadakis, E

    1. Ciclazindol inhibits ATP-sensitive K+ channels and stimulates insulin secretion in CR1-G1 insulin-secreting cells.
      K Lee, R N Khan, I C Rowe, S E Ozanne, A C Hall, E Papadakis, C N Hales and M L Ashford
      Molecular Pharmacology April 1996, 49 (4) 715-720;

  3. Pessah, I N

    1. Ortho-substituted polychlorinated biphenyls alter calcium regulation by a ryanodine receptor-mediated mechanism: structural specificity toward skeletal- and cardiac-type microsomal calcium release channels.
      P W Wong and I N Pessah
      Molecular Pharmacology April 1996, 49 (4) 740-751;

  4. Pizzi, M

    1. Metabotropic and ionotropic transducers of glutamate signal inversely control cytoplasmic Ca2+ concentration and excitotoxicity in cultured cerebellar granule cells: pivotal role of protein kinase C.
      M Pizzi, P Galli, O Consolandi, V Arrighi, M Memo and P F Spano
      Molecular Pharmacology April 1996, 49 (4) 586-594;

  5. Pommier, Y

    1. Effects of nucleotide analogues on human immunodeficiency virus type 1 integrase.
      A Mazumder, N Neamati, J P Sommadossi, G Gosselin, R F Schinazi, J L Imbach and Y Pommier
      Molecular Pharmacology April 1996, 49 (4) 621-628;

R

  1. Racagni, G

    1. Cyclic AMP-dependent regulation of fibroblast growth factor-2 messenger RNA levels in rat cortical astrocytes: comparison with fibroblast growth factor-1 and ciliary neurotrophic factor.
      M A Riva, R Molteni, E Lovati, F Fumagalli, M Rusnati and G Racagni
      Molecular Pharmacology April 1996, 49 (4) 699-706;

  2. Riva, M A

    1. Cyclic AMP-dependent regulation of fibroblast growth factor-2 messenger RNA levels in rat cortical astrocytes: comparison with fibroblast growth factor-1 and ciliary neurotrophic factor.
      M A Riva, R Molteni, E Lovati, F Fumagalli, M Rusnati and G Racagni
      Molecular Pharmacology April 1996, 49 (4) 699-706;

  3. Rousell, J

    1. Beta-Adrenoceptor-medicated down-regulation of M2 muscarinic receptors: role of cyclic adenosine 5'-monophosphate-dependent protein kinase and protein kinase C.
      J Rousell, E B Haddad, J C Mak, B L Webb, M A Giembycz and P J Barnes
      Molecular Pharmacology April 1996, 49 (4) 629-635;

  4. Rousseau, G

    1. Distinct receptor domains determine subtype-specific coupling and desensitization phenotypes for human beta1- and beta2-adrenergic receptors.
      G Rousseau, F Nantel and M Bouvier
      Molecular Pharmacology April 1996, 49 (4) 752-760;

  5. Rowe, I C

    1. Ciclazindol inhibits ATP-sensitive K+ channels and stimulates insulin secretion in CR1-G1 insulin-secreting cells.
      K Lee, R N Khan, I C Rowe, S E Ozanne, A C Hall, E Papadakis, C N Hales and M L Ashford
      Molecular Pharmacology April 1996, 49 (4) 715-720;

  6. Rusnati, M

    1. Cyclic AMP-dependent regulation of fibroblast growth factor-2 messenger RNA levels in rat cortical astrocytes: comparison with fibroblast growth factor-1 and ciliary neurotrophic factor.
      M A Riva, R Molteni, E Lovati, F Fumagalli, M Rusnati and G Racagni
      Molecular Pharmacology April 1996, 49 (4) 699-706;

S

  1. Schinazi, R F

    1. Effects of nucleotide analogues on human immunodeficiency virus type 1 integrase.
      A Mazumder, N Neamati, J P Sommadossi, G Gosselin, R F Schinazi, J L Imbach and Y Pommier
      Molecular Pharmacology April 1996, 49 (4) 621-628;

  2. Schoepp, D D

    1. Pharmacological discrimination of GluR5 and GluR6 kainate receptor subtypes by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahyd roisdoquinoline-3 carboxylic-acid.
      R Bleakman, D D Schoepp, B Ballyk, H Bufton, E F Sharpe, K Thomas, P L Ornstein and R K Kamboj
      Molecular Pharmacology April 1996, 49 (4) 581-585;

  3. Separovic, D

    1. Coupling of I1-imidazoline receptors to diacylglyceride accumulation in PC12 rat pheochromocytoma cells.
      D Separovic, M Kester and P Ernsberger
      Molecular Pharmacology April 1996, 49 (4) 668-675;

  4. Sharpe, E F

    1. Pharmacological discrimination of GluR5 and GluR6 kainate receptor subtypes by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahyd roisdoquinoline-3 carboxylic-acid.
      R Bleakman, D D Schoepp, B Ballyk, H Bufton, E F Sharpe, K Thomas, P L Ornstein and R K Kamboj
      Molecular Pharmacology April 1996, 49 (4) 581-585;

  5. Shu, L L

    1. Separation of resistance to antitumor diarylsulfonylurea agents from collateral sensitivity to mitochondrial toxins.
      L L Shu and P J Houghton
      Molecular Pharmacology April 1996, 49 (4) 595-601;

  6. Sommadossi, J P

    1. Effects of nucleotide analogues on human immunodeficiency virus type 1 integrase.
      A Mazumder, N Neamati, J P Sommadossi, G Gosselin, R F Schinazi, J L Imbach and Y Pommier
      Molecular Pharmacology April 1996, 49 (4) 621-628;

  7. Spano, P F

    1. Metabotropic and ionotropic transducers of glutamate signal inversely control cytoplasmic Ca2+ concentration and excitotoxicity in cultured cerebellar granule cells: pivotal role of protein kinase C.
      M Pizzi, P Galli, O Consolandi, V Arrighi, M Memo and P F Spano
      Molecular Pharmacology April 1996, 49 (4) 586-594;

  8. Spilman, C H

    1. Unusual steroid specificity of the cell surface progesterone receptor on human sperm.
      P F Blackmore, J F Fisher, C H Spilman and J E Bleasdale
      Molecular Pharmacology April 1996, 49 (4) 727-739;

  9. Svoboda, P

    1. Thyrotropin-releasing hormone-induced subcellular redistribution and down-regulation of G11alpha: analysis of agonist regulation of coexpressed G11alpha species variants.
      P Svoboda, G D Kim, M A Grassie, K A Eidne and G Milligan
      Molecular Pharmacology April 1996, 49 (4) 646-655;

T

  1. Tanaka, H

    1. Modulation of glucocorticoid-inducible gene expression by metal ions.
      Y Makino, H Tanaka, K Dahlman-Wright and I Makino
      Molecular Pharmacology April 1996, 49 (4) 612-620;

  2. Thomas, K

    1. Pharmacological discrimination of GluR5 and GluR6 kainate receptor subtypes by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahyd roisdoquinoline-3 carboxylic-acid.
      R Bleakman, D D Schoepp, B Ballyk, H Bufton, E F Sharpe, K Thomas, P L Ornstein and R K Kamboj
      Molecular Pharmacology April 1996, 49 (4) 581-585;

W

  1. Webb, B L

    1. Beta-Adrenoceptor-medicated down-regulation of M2 muscarinic receptors: role of cyclic adenosine 5'-monophosphate-dependent protein kinase and protein kinase C.
      J Rousell, E B Haddad, J C Mak, B L Webb, M A Giembycz and P J Barnes
      Molecular Pharmacology April 1996, 49 (4) 629-635;

  2. Werner, P

    1. D2, D3, and D4 dopamine receptors couple to G protein-regulated potassium channels in Xenopus oocytes.
      P Werner, N Hussy, G Buell, K A Jones and R A North
      Molecular Pharmacology April 1996, 49 (4) 656-661;

  3. Wess, J

    1. Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition.
      J Kim, Q Jiang, M Glashofer, S Yehle, J Wess and K A Jacobson
      Molecular Pharmacology April 1996, 49 (4) 683-691;

  4. Whitney, R A

    1. Isolation of N-vinylprotoporphyrin IX after hepatic cytochrome P450 inactivation by 3-[(arylthio)ethyl]sydnone in chick embryos pretreated with phenobarbital, glutethimide, dexamethasone, and beta-naphthoflavone: differential inhibition of ferrochelatase by N-vinylprotoporphyrin regioisomers.
      S M Kimmett, R A Whitney and G S Marks
      Molecular Pharmacology April 1996, 49 (4) 676-682;

  5. Wong, P W

    1. Ortho-substituted polychlorinated biphenyls alter calcium regulation by a ryanodine receptor-mediated mechanism: structural specificity toward skeletal- and cardiac-type microsomal calcium release channels.
      P W Wong and I N Pessah
      Molecular Pharmacology April 1996, 49 (4) 740-751;

Y

  1. Yehle, S

    1. Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition.
      J Kim, Q Jiang, M Glashofer, S Yehle, J Wess and K A Jacobson
      Molecular Pharmacology April 1996, 49 (4) 683-691;
Back to top

In this issue